Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $467.46M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 0.79M
Average 0.69M
STTK Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Shattuck Labs, Inc.NASDAQ: STTK
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin not reported for Q1 FY2026
Over 3 fiscal years it widened by 10697.2 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 6 analysts of -33519.1% for the fiscal year ending Dec 2026, down from -5150.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- —— QoQ
- Last fiscal yearDec 2025
- -5150.8%-3742.5 pp YoY
- LTMMar 2026
- -5266.4%-3640.0 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -5150.8%
- Year-over-year change
- -3742.5pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -5150.8% | -3742.5pp |
| FY2024 | 2024-12-31 | -1408.3% | +4141.3pp |
| FY2023 | 2023-12-31 | -5549.6% | +10298.4pp |
| FY2022 | 2022-12-31 | -15848.0% | -15697.2pp |
| FY2021 | 2021-12-31 | -150.8% | — |
Operating Margin vs competitors
How STTK compares with its peers on the latest reported figures
- STTK's LTM Mar 2026 operating margin of -5266.4% is the lowest of the 6 companies compared; the peer median is 13.0%.
- Its year-over-year change of -3640.0 pp is the lowest of 3, against a peer median of +50.2 pp.
- Over three fiscal years its change of +10697.2 pp compares with a peer median of +30901.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 4098.5% | — | — | |
| FY2025 | 28.4% | — | — | |
| LTM Mar 2026 | 13.0% | -3.0 pp | +5.9 pp | |
| LTM Sep 2026 | -60.8% | +103.5 pp | — | |
| LTM Mar 2026 | -1372.9% | — | +61796.9 pp | |
| LTM Mar 2026 | -5266.4% | -3640.0 pp | +10697.2 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NBPNovaBridge Biosciences | FY2025 | — | — | — |
| Peer median (excluding STTK) | 13.0% | +50.2 pp | +30901.4 pp | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.02M | 652K | 1.66M | 5.72M | 1M |
| Cost of Revenue | 1.38M | 82.2M | 4.04M | 4.89M | 0 |
| Gross Profit | 28.64M | (81.55M) | (2.39M) | 827K | 1M |
| Gross Margin | 95.4% | -12507.2% | -143.9% | 14.5% | 100.0% |
| Research & Development | 56.56M | 82.9M | 74.31M | 67.21M | 35.27M |
| Selling, General & Admin | 18.72M | 19.68M | 19.3M | 19.08M | 17.24M |
| Operating Expenses | 73.91M | 21.78M | 89.57M | 81.39M | 52.51M |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| EBITDA | (43.59M) | (98.87M) | (83.26M) | (71.58M) | (45.12M) |
| EBITDA Margin | -145.2% | -15164.4% | -5024.5% | -1251.2% | -4512.1% |
| Operating Income | (45.27M) | (103.33M) | (91.96M) | (80.57M) | (51.51M) |
| Operating Margin | -150.8% | -15848.0% | -5549.6% | -1408.3% | -5150.8% |
| Interest Income | 625K | 1.59M | 4.67M | 5.17M | 2.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 295K | 1.38M | 4.66M | 5.16M | 2.7M |
| Income Before Tax | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Pre-Tax Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Net Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| EPS (Basic) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| EPS (Diluted) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| Weighted Avg Shares | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
| Weighted Avg Shares (Diluted) | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.